Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/emnpCfbwocfDtyxNVcnx

March 6, 2013
Sign upForwardArchive
News for the PBM Industry

  Featured Story 
  • Humira, Advair, Rituxan lead list of best-selling drugs in 2012
    AbbVie's Humira, or adalimumab, topped this list of last year's 20 best-selling drugs based on publicly available figures. GlaxoSmithKline's Advair, or fluticasone and salmeterol, came in second, followed by Roche Holding's Rituxan, or rituximab. Rounding out the top 10 were Sanofi's Lantus, Roche's Herceptin, AstraZeneca's Crestor, Johnson & Johnson's Remicade, Roche's Avastin, Eli Lilly and Co.'s Cymbalta, and Sanofi and Bristol-Myers Squibb's Plavix. Genetic Engineering & Biotechnology News (3/5) LinkedInFacebookTwitterEmail this Story
 Registration is now open for PCMA's Specialty Pharmacy Business Forum!
The SPBF provides individuals and companies in the specialty pharmacy chain of commerce with exceptional educational and business networking opportunities. A unique aspect of the conference is "PCMA-Connect," an online networking community that will give attendees the opportunity to search for, connect, and coordinate meetings with existing and potential business customers and partners.
 

  Legislative & Regulatory News 
  • Parties disagree on effects of cuts to MA plans
    Democrats say further reductions in federal subsidies to private Medicare Advantage plans will reduce spending without harming benefits, citing a Government Accountability Office report that revealed $3.2 billion in overpayments from 2010 to 2012. Republicans counter that subsidy cuts will result in greater cost-sharing and reduced benefits for enrollees. MedPage Today (free registration) (3/5) LinkedInFacebookTwitterEmail this Story
  • HHS makes plans to publicize new health coverage options
    HHS plans to start advertising in July the availability of health insurance through public marketplaces and the expansion of Medicaid eligibility, though enrollment is not open until October and coverage would not begin until January. HHS plans to work with hospitals and community organizations to spread the word. Politico (Washington, D.C.) (3/6) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Regulators extend Pfizer's patent on Celebrex
    The U.S. Patent & Trademark Office extended the patent on Pfizer's Celebrex until Dec. 2, 2015, for arthritis and other conditions, extending market exclusivity by a year and a half. Pfizer filed suit against Teva Pharmaceutical Industries, Mylan, Actavis (formerly Watson), Lupin and Apotex to block U.S. sales of generic versions beginning in May 2014. Reuters (3/5) LinkedInFacebookTwitterEmail this Story
  SmartQuote 
Every time you spend money, you're casting a vote for the kind of world you want."
--Anna Lappé,
American writer, speaker and activist


LinkedInFacebookTwitter

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

 
Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
 
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 
 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information